Faeth Therapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Faeth Therapeutics, Inc. (FTH) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $770.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-04
- Faeth Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $389.00K, a 8.36% increase year-over-year.
- Faeth Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $381.00K, a 7.30% decline year-over-year.
- Faeth Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $374.00K, a 7.20% decline year-over-year.
- Faeth Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $366.00K, a 7.11% decline year-over-year.
- Faeth Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.51M, a 2.83% decline from fiscal 2024.
- Faeth Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.55M, a 14.52% increase from fiscal 2023.
- Faeth Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.36M, a 13.65% increase from fiscal 2022.
- Faeth Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $1.19M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $389.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $770.00K 10-Q · filed 2026-08-04 | $1.14M derived: sum of 3 quarters · filed 2026-08-04 | $1.51M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $381.00K 10-Q · filed 2026-05-15 | $755.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.12M derived: sum of 3 quarters · filed 2026-05-15 | $1.48M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $374.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $740.00K derived: sum of 2 quarters · filed 2026-03-30 | $1.10M derived: sum of 3 quarters · filed 2026-08-04 | $1.51M 10-K · filed 2026-03-30 |
| 2025-09-30 | $366.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $725.00K derived: sum of 2 quarters · filed 2026-08-04 | $1.14M 10-Q · filed 2025-11-14 | $1.54M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $359.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $770.00K 10-Q · filed 2026-08-04 | $1.17M derived: sum of 3 quarters · filed 2026-08-04 | $1.57M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $411.00K 10-Q · filed 2026-05-15 | $814.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.21M derived: sum of 3 quarters · filed 2026-05-15 | $1.59M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $403.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $797.00K derived: sum of 2 quarters · filed 2026-03-30 | $1.18M derived: sum of 3 quarters · filed 2026-03-30 | $1.55M 10-K · filed 2026-03-30 |
| 2024-09-30 | $394.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $781.00K derived: sum of 2 quarters · filed 2025-11-14 | $1.15M 10-Q · filed 2025-11-14 | $1.52M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $387.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $757.00K 10-Q · filed 2025-08-05 | $1.13M derived: sum of 3 quarters · filed 2025-08-05 | $1.45M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $370.00K 10-Q · filed 2025-05-06 | $740.00K derived: sum of 2 quarters · filed 2025-05-06 | $1.06M derived: sum of 3 quarters · filed 2025-05-06 | $1.41M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $370.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $688.00K derived: sum of 2 quarters · filed 2025-03-28 | $1.04M derived: sum of 3 quarters · filed 2025-03-28 | $1.36M 10-K · filed 2025-03-28 |
| 2023-09-30 | $318.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $671.00K derived: sum of 2 quarters · filed 2024-11-14 | $987.00K 10-Q · filed 2024-11-14 | $1.29M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $353.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $669.00K 10-Q · filed 2024-08-06 | $976.00K derived: sum of 3 quarters · filed 2024-08-06 | $1.28M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $316.00K 10-Q · filed 2024-05-09 | $623.00K derived: sum of 2 quarters · filed 2024-05-09 | $923.00K derived: sum of 3 quarters · filed 2024-05-09 | $1.22M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $307.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $607.00K derived: sum of 2 quarters · filed 2024-02-29 | $903.00K derived: sum of 3 quarters · filed 2024-02-29 | $1.19M 10-K · filed 2024-02-29 |
| 2022-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $596.00K derived: sum of 2 quarters · filed 2023-11-07 | $887.00K 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $296.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $587.00K 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $291.00K 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |